Evommune Doses First Patient in Migraine Trial
The Phase 2b study will enroll approximately 330 patients across two dose arms and placebo.
Evommune (EVMN), a biotechnology company developing therapies for immune-mediated diseases, dosed the first patient in a Phase 2b trial of EVO756 for migraine.
The milestone shifted attention to migraine after a 160-patient Phase 2b study in chronic spontaneous urticaria failed its primary endpoint at every dose in June. Evommune ended development in that indication and continued advancing EVO756 in migraine and atopic dermatitis.
The migraine program progressed from a planned mid-2026 trial start disclosed between March and May to patient screening by June 29, when dosing was expected imminently. The first patient received treatment by July 30.
Participants will receive one of two active doses or placebo for 12 weeks, with daily doses of up to 100 milligrams. Evommune expects top-line results in 2027.
The primary endpoint is the change from baseline in monthly migraine days. Key secondary measures include the proportions of patients achieving reductions of at least 50% and 75%, along with changes in monthly headache days and acute-medication use.
The trial now carries EVO756’s lead clinical test after the urticaria setback, with the 2027 data expected to determine whether the drug’s remaining development path gains support from migraine patients.